Asthma management has two modes: chronic control and acute exacerbation. The step-based approach to chronic management is determined by symptom frequency and impact — not just whether symptoms exist. ICS is the cornerstone. LABA without ICS is dangerous.
CLINICAL PRINTABLE
Coming Soon.
A one-page Asthma — Control, Exacerbation, and the Treatment Step clinical reference is on the way.
1 · Recognition / Control Assessment
- Assess control at every visit: daytime symptoms, nighttime awakenings, activity limitation, and rescue inhaler use frequency determine the control category (well-controlled, not well-controlled, very poorly controlled).
- Distinguish persistent from intermittent asthma — intermittent disease has symptoms 2 or fewer days per week with no interference with normal activity.
- Identify triggers: allergens, exercise, cold air, NSAID/aspirin sensitivity, GERD, sinusitis, vocal cord dysfunction, and occupational exposures.
- Assess exacerbation severity: mild (speaks in sentences, SpO2 ≥95%, mild wheeze), moderate (speaks in phrases, SpO2 91–94%, accessory muscle use), severe (speaks in words, SpO2 <91%, paradoxical breathing, silent chest).
2 · Step-Based Treatment Pathway
Step 1 — Intermittent asthma
SABA (albuterol) PRN for symptom relief. No daily controller medication required. Consider low-dose ICS-formoterol PRN as an alternative in appropriate patients.
Step 2 — Mild persistent
Low-dose inhaled corticosteroid (ICS) daily plus SABA PRN. ICS is the cornerstone of persistent asthma management — it reduces airway inflammation, exacerbations, and asthma mortality.
Step 3 — Moderate persistent
Low-dose ICS plus long-acting beta-agonist (LABA) or medium-dose ICS. LABA should never be used without ICS in asthma — LABA monotherapy increases asthma mortality.
Step 4 — Severe persistent
Medium-dose ICS plus LABA. Consider adding LAMA, LTRA, or theophylline. Evaluate for biologic eligibility (eosinophilic or allergic phenotype).
Step 5–6 — Very severe
High-dose ICS plus LABA plus additional controller. Biologics (dupilumab, mepolizumab, benralizumab, omalizumab) for appropriate phenotypes. Oral corticosteroids as last resort.
3 · Exacerbation Management
- Mild-moderate exacerbation: SABA every 20 minutes x3, then reassess. Add ipratropium for moderate-severe. Systemic corticosteroids for moderate-severe or inadequate response to SABA.
- Severe exacerbation: continuous SABA, ipratropium, IV/oral corticosteroids, supplemental oxygen to maintain SpO2 93–95%, consider IV magnesium sulfate.
- Heliox, IV beta-agonists, and intubation for refractory severe exacerbation — intubation in asthma carries high risk; avoid if possible.
- Discharge criteria: SpO2 ≥95% on room air, SABA use ≤every 4 hours, near-normal exam. Prescribe oral corticosteroid course, step up controller therapy, and arrange follow-up.
4 · Expected Response / Monitoring
- ICS reduces exacerbation frequency and severity over weeks to months — patients should not expect immediate symptom relief from ICS (unlike SABA).
- Reassess control and step at every visit — step up if not well-controlled, step down if well-controlled for 3 months.
- Poor response to ICS should prompt assessment of inhaler technique, adherence, trigger avoidance, and diagnosis confirmation before stepping up.
5 · Escalation
- Status asthmaticus: severe bronchospasm not responding to standard therapy — ICU-level care, continuous bronchodilators, IV magnesium, possible intubation.
- Respiratory failure: silent chest, paradoxical breathing, altered mentation, SpO2 <90% despite supplemental oxygen — immediate intervention.
- Pulmonology referral for severe/refractory asthma, biologic candidacy evaluation, or diagnostic uncertainty.
Apply It · Change One Detail
APPLY IT
A patient with known asthma uses albuterol 4–5 times per week and wakes up twice per week with symptoms. That is not well-controlled asthma — it is at minimum Step 3 disease. The question is whether they are on a controller and whether it is adequate.
CHANGE ONE DETAIL
Change one detail — the same patient uses albuterol once per week with no nighttime symptoms and no activity limitation. That is well-controlled asthma. If they have been on Step 3 therapy for 3 months, a step-down trial is appropriate.
Bottom Line
LABA monotherapy in asthma increases mortality — always pair LABA with ICS. ICS is the cornerstone of persistent asthma management.
EVIDENCE & REFERENCES
- NAEPP Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. NIH Publication 08-4051. 2007. https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma
- GINA Report. Global Strategy for Asthma Management and Prevention. 2024. https://ginasthma.org